Genetic Alteration After Systemic Treatment in Breast Cancer

Prospective single arm trial using three patients' cohorts. One-hundred patients for each cohort and a total of 300 patients (600 biopsy samples) will be entered to this trial. The hypothesis is that genomic alterations measured by CancerSCAN and cfDNA, Whole exome sequencing (WES), Whole transcriptome sequencing (WTS), FACS(Fluorescence-Activated Cell Sorting), cytokine and immunologic signature analysis would be different between pre- and post-menopausal women and would be predictive biomarkers for each cohort according to pre- and post-menopausal status. Three groups of patients will be recruited: 1. The patients who receive neoadjuvant systemic treatments: 2. The patients who have distant metastatic sites at first and recur from surgery: 3. The patients who are going to receive first-line chemotherapy